Edition:
India

Conatus Pharmaceuticals Inc (CNAT.OQ)

CNAT.OQ on NASDAQ Stock Exchange Global Market

4.27USD
15 Dec 2017
Change (% chg)

$0.18 (+4.40%)
Prev Close
$4.09
Open
$4.10
Day's High
$4.30
Day's Low
$4.05
Volume
143,382
Avg. Vol
66,710
52-wk High
$9.40
52-wk Low
$1.88

Summary

Name Age Since Current Position

David Hale

67 2012 Independent Chairman of the Board

Steven Mento

65 2017 President, Chief Executive Officer, Director

Keith Marshall

2017 Chief Financial Officer, Principal Financial Officer, Chief Operating Officer, Executive Vice President

Alfred Spada

57 2015 Executive Vice President - Research & Development, Chief Scientific Officer

David Hagerty

60 2014 Executive Vice President, Clinical Development

Daniel Ripley

2017 Senior Vice President - Business Development, Program and Alliance Management

Edward Smith

2016 Senior Vice President - Regulatory Affairs and Quality Assurance

Michelle Vandertie

53 2017 Acting Principal Accounting Officer

Daniel Kisner

70 2014 Additional Independent Director

Preston Klassen

48 2014 Additional Independent Director

William LaRue

66 2017 Additional Independent Director

James Scopa

58 2011 Independent Director

Harold Van Wart

69 2007 Independent Director

Biographies

Name Description

David Hale

Mr. David F. Hale is the Independent Chairman of the Board of Conatus Pharmaceuticals Inc. Since May 2006, he has served as Chairman & CEO of Hale BioPharma Ventures. He was previously President and CEO of CancerVax Corporation which merged with Micromet, Inc from October 2000 through May 2006, when he became Chairman of the combined companies. He is a serial entrepreneur who has been involved in the founding and/or development of a number of biotechnology and specialty pharmaceutical companies. After joining Hybritech, Inc., in 1982, he was President & Chief Operating Officer and became CEO in 1986. From 1987 to 1997 he was Chairman, President and CEO of Gensia, Inc. He was a co-founder and Chairman of Viagene, Inc. from 1987 to 1995. He was President and CEO of Women First HealthCare, Inc. from late 1997 to June 2000. Prior to joining Hybritech, he was Vice President and General Manager of BBL Microbiology Systems and from 1971 to 1980, held various marketing and sales management positions with Ortho Pharmaceutical Corporation, a division of Johnson & Johnson, Inc. Mr. Hale is Chairman of Santarus, Inc and previously served as Chairman of Somaxon, Inc. prior to its acquisition in 2013. He also serves as Chairman of Colorescience, Inc., Ridge Diagnostics, Crisi, Inc., Intrepid Therapeutics, Neurelis, Inc., Agility Clinical, Advantar Laboratories, Inc. and Katama Pharmaceuticals, Inc. He also is a co-founder and serves on the Board of Directors of BIOCOM, is a former member of the Board of the Biotechnology Industry Organization (BIO), and the Biotechnology Institute. He also serves on the Board of Directors of the San Diego Economic Development Corporation, and as Chairman of the Board of Trustees of Rady Children’s Hospital of San Diego. He is a co-founder of the CONNECT Program in Technology and Entrepreneurship. Mr. Hale holds a B.A. in Biology and Chemistry from Jacksonville State University.

Steven Mento

Dr. Steven J. Mento, Ph.D., is appointed as President, Chief Executive Officer, Director of Conatus Pharmaceuticals Inc. He is one of co-founders and has served as President and Chief Executive Officer and as a member of board of directors since July 2005. From July 2005 until December 2012, he also served as chairman of the board of directors. He has over 30 years of combined experience in the biotechnology and pharmaceutical industries. From 1997 to 2005, he was President, Chief Executive Officer and a member of the Board of Directors of Idun Pharmaceuticals, Inc. He guided Idun during its transition from a discovery focused organization to a drug development company with multiple products in or near human clinical testing. In April 2005, Idun was sold to Pfizer Inc. Previously, he served as President of Chiron Viagene, Inc. (subsequently Chiron Technologies, Center for Gene Therapy), and Vice President of Chiron Corporation from 1995 to 1997. He was Vice President of R&D at Viagene from 1992 to 1995. Prior to Viagene, he held various positions at American Cyanamid Company from 1982 to 1992. His last position was Director of Viral Vaccine Research and Development at Lederle-Praxis Biologicals, a business unit of American Cyanamid. He serves on the boards of directors of BIOCOM, the Biotechnology Industry Organization (BIO), BIO Emerging Company Section Governing Body, BIO Health Section Governing Body, Sangamo Biosciences, Inc., and various academic and charitable organizations. Dr. Mento holds a B.A. in Microbiology from Rutgers College, and an M.S. and Ph.D. both in Microbiology from Rutgers University.

Keith Marshall

Mr. Keith W. Marshall, Ph.D. is Chief Financial Officer, Principal Financial Officer, Chief Operating Officer, Executive Vice President of the company. He has been Chief Financial Officer and Head of Corporate Development since 2015 at Torque Therapeutics, where his responsibilities included finance, operations, human resources, corporate strategy and business development. He served as Managing Director and Advisor in Healthcare Investment Banking from 2012 to 2014 at GCA Savvian Advisors, where he provided strategic counsel to healthcare companies, and continued from 2014 to 2015 at TAG Healthcare Advisors under an alliance with GCA Savvian. Dr. Marshall was Managing Director from 2011 to 2012 at Sagent Advisors; Managing Director, Co-founder, and Chief Financial Officer from 2008 to 2011 at Montgomery, Marshall Healthcare Partners; Managing Director of Healthcare Investment Banking from 2003 to 2008 at Montgomery & Co.; and Associate in Healthcare Investment Banking from 2001 to 2003 at JPMorgan H&Q with additional responsibilities at JPMorgan Partners. Dr. Marshall previously worked as a Research Associate from 1990 to 1993 at ImmuLogic Pharmaceutical Corporation, where he performed research under a collaboration with Merck around inhibition of MHC Class II molecules for autoimmune disease therapy. He holds an M.B.A. with concentrations in Finance, Strategy, and Entrepreneurship from the University of Chicago – Booth School of Business; a Ph.D. in Pharmaceutical Chemistry from the University of California, San Francisco; and an A.B. in Biology from Washington University in St. Louis.

Alfred Spada

Dr. Alfred P. Spada, Ph.D., has been promoted as Executive Vice President - Research & Development, Chief Scientific Officer of Company. He was Senior Vice President of Research and Development, Chief Scientific Officer of Conatus Pharmaceuticals Inc. He is one of co-founders and has served as Senior Vice President, Research and Development since July 2005, and as Chief Scientific Officer since April 2012. He has over 28 years of experience in the pharmaceutical and biotechnology industries. He has co-authored more than 50 scientific publications and is an inventor on more than 70 patents. From 2000 to 2005, Dr. Spada was Vice President of Pharmaceutical and Preclinical Development at Idun Pharmaceuticals where he was responsible for managing internal research and development activities, and Idun’s external partnerships, including the collaboration with Abbott Laboratories. Prior to joining Idun, he was a Department Director at Aventis Pharmaceuticals (formerly Rhone-Poulenc Rorer), where he was responsible for medicinal and analytical chemistry. From 1990 to 2000, his teams worked on a wide variety of enzyme-based and G-protein coupled receptors (GCPR) targets, resulting in the identification of clinical candidates for treatment of acute myocardial infarction, thrombotic disorders, coronary restenosis, lipid lowering, diabetes and cancer. His team discovered otamixaban, a direct acting factor Xa inhibitor currently in Phase 3 clinical trials for the treatment of acute coronary syndrome. Dr. Spada holds a B.S. in Chemistry from Worcester Polytechnic Institute and a Ph.D. in Chemistry from the Massachusetts Institute of Technology.

David Hagerty

Mr. David T. Hagerty, M.D is the Executive Vice President, Clinical development since October 2014. Dr. Hagerty has over 18 years of experience in the pharmaceutical and biotechnology industries. Dr. Hagerty has been an independent consultant in clinical development since April 2013. He served as Senior Vice President and Chief Medical Officer at Ardea Biosciences from 2011 to 2013. He previously served as a Vice President of Immunology and Rheumatology Clinical Research at Biogen Idec Inc. from 2006 to 2011, where he led the clinical development of rituximab for rheumatoid arthritis and lupus with joint development partner Genentech. Previously, Dr. Hagerty advanced through several management roles at the Bristol-Myers Squibb Pharmaceutical Research Institute from 1997 through 2006, most recently as Executive Director of Immunology Global Clinical Research and medical lead for the abatacept clinical development program. His earlier career included faculty and laboratory research duties at Washington University School of Medicine. Dr. Hagerty served for five years in the Medical Corps of the United States Navy, and was recalled to Active Duty in Operation Desert Storm. Dr. Hagerty received an M.D. degree from St. Louis University of Medicine and a B.S. degree from the University of Notre Dame. He is Board Certified in internal medicine and nephrology, and has been United Network for Organ Sharing (UNOS) certified as a transplant physician.

Daniel Ripley

Mr. Daniel L. Ripley serves as Senior Vice President - Business Development, Program and Alliance Management of Conatus Pharmaceuticals Inc. He has 15 years of integrated business development experience in the initiation and execution of strategic business transactions in emerging growth life science companies. He has led licensing, commercial analysis, partnering initiatives, and intellectual property enforcement to drive business development of early-to-late stage products in a wide variety of therapeutic areas and technologies. He served as Senior Director of Business Development at Apricus Biosciences from 2011 through 2012, and prior to that was a senior business development consultant to biotechnology companies in the San Diego area from 2010 through 2011, Vice President of Business Development at BioBlocks, Inc. from 2009 through 2010, Senior Director, Head of Business Development at Kalypsys, Inc. from 2006 through 2008, and Director of Business Development at Isis Pharmaceuticals from 2000 through 2006. During this timeframe, he executed multiple licensing and drug discovery collaborations with pharmaceutical and biotechnology companies that included Pfizer, Oncogenex, Alnylam, Amgen, GSK, Sanofi, and Alcon. Mr. Ripley holds an M.B.A. with an emphasis in Finance and a B.S. in Microbiology, both from San Diego State University.

Edward Smith

Dr. Edward F. Smith III., Ph.D. is Senior Vice President - Regulatory Affairs and Quality Assurance of the company. He has been Vice President, Regulatory Affairs and Drug Safety at Zogenix, Inc., since October 2008, which he joined as Senior Director, Regulatory Affairs in April 2007. Before joining Zogenix, he served as Senior Director, Regulatory Affairs at Connetics Corp. from 2006 to 2007; Director, Regulatory Affairs at Nektar Therapeutics from 2004 to 2006; Director, Corporate Regulatory Affairs at Valeant Pharmaceuticals from 2001 to 2004; and Vice President, Regulatory Affairs and Research & Development at Radiance Medical Systems, Inc., from 1999 to 2001. He previously held research and development positions at Mallinckrodt Inc. from 1992 to 1999, at SmithKline Beecham Pharmaceuticals from 1986 to 1992, and at Ciba-Geigy from 1984 to 1985. Dr. Smith held postdoctoral fellowships at the Institute of Pharmacology at the University of Koln in Germany, and the Medical University of South Carolina. Dr. Smith received a B.S. in biology from Montana State University, a Ph.D. in physiology from Thomas Jefferson University, and an M.B.A. from Washington University. He also holds a Regulatory Affairs Certification.

Michelle Vandertie

Ms. Michelle L. Vandertie is appointed as Acting Principal Accounting Officer of the company effective March 31, 2017. She has served as the Company’s Vice President, Finance since March 2016. Ms. Vandertie served as the Company’s Controller from October 2007 through March 2016. From January 2007 through October 2007, Ms. Vandertie served as an accounting consultant for the Company. Ms. Vandertie has held several management level positions in both private and public companies and served as an auditor with Ernst & Young LLP from 1987 to 1990. Ms. Vandertie received her bachelor’s degree from the University of Northern Colorado.

Daniel Kisner

Dr. Daniel L. Kisner, M.D. is an Additional Independent Director of the Company. Dr. Kisner serves as an independent consultant in the life science industry. He was a partner at Aberdare Ventures from 2003 to 2011. Dr. Kisner served as Chairman of the Board of Directors of Caliper Life Sciences from 2002 to 2008, and as President and CEO of its predecessor company, Caliper Technologies, from 1999 to 2002. He held positions of increasing responsibility at Isis Pharmaceuticals, Inc., from 1991 to 1999, most recently as President and COO. Dr. Kisner previously served in pharmaceutical research and development executive positions at Abbott Laboratories from 1988 to 1991 and at SmithKline Beckman Laboratories from 1985.

Preston Klassen

Dr. Preston S. Klassen, M.D., M.H.S. is an Additional Independent Director of the Company. Dr. Klassen has served as Senior Vice President and Head of Global Development at Orexigen Therapeutics, Inc., since 2009. He advanced from 2002 to 2009 through several medical director positions at Amgen, Inc., most recently as Therapeutic Area Head for Nephrology and Executive Medical Director. His experience at Amgen included global regulatory filings, design and conduct of large clinical trials, clinical commercialization of multiple products, and active leadership in regulatory agency interactions. Dr. Klassen was a faculty member in the Division of Nephrology at Duke University Medical Center from 1997 to 2002. He received his M.D. from the University of Nebraska College of Medicine and completed his residency in Internal Medicine, fellowship in Nephrology, and M.H.S. degree at Duke University.

William LaRue

Mr. William R. LaRue serves as Additional Independent Director of the Company. Mr. LaRue joined Cadence Pharmaceuticals, Inc., a biopharmaceutical company, as Senior Vice President and Chief Financial Officer in June 2006, and expanded his role to serve as Assistant Secretary at Cadence in April 2007, serving in both capacities until the company's acquisition by Mallinckrodt plc in March 2014. At Cadence, Mr. LaRue was a member of the Executive Committee with direct responsibility for the company's financial leadership including corporate financing, investor relations, financial planning and reporting, SEC reporting, accounting, treasury, risk management, tax and information technology. uring his tenure, Cadence raised over $375 million in public and private equity and senior debt, including an IPO in October 2006 as the company transitioned from a development stage to a commercial stage company. Prior to joining Cadence, Mr. LaRue served as the Senior Vice President and Chief Financial Officer of CancerVax Corporation, a biotechnology company, from 2001 until its merger with Micromet, Inc. in May 2006. He served from 2000 to 2001 as the Executive Vice President and Chief Financial Officer of eHelp Corporation, a provider of user assistance software; from 1997 to 2000 as the Vice President and Treasurer of Safeskin Corporation, a medical device company; and from 1993 to 1997 as the Treasurer of GDE Systems, Inc., a high technology electronic systems company. Mr. LaRue currently serves as a member of the Board of Directors and Chair of the Audit Committee of Tracon Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, and as a member of the Board of Directors and Chair of Audit Committee of Applied Proteomics, Inc., a private, venture-backed, molecular diagnostics company. He previously served on the boards of directors of Cadence Pharmaceuticals, Inc. and Neurelis, Inc., a specialty pharmaceutical company. Mr. LaRue received a B.S. in business administration and an M.B.A. from the University of S

James Scopa

Mr. James P. Scopa serves as Independent Director of Conatus Pharmaceuticals Inc. He is a Managing Director in MPM Capital’s San Francisco office, having joined the firm in 2005. Previously, he spent 18 years advising growth companies in biopharmaceuticals and medical devices at Deutsche Banc Alex. Brown and Thomas Weisel Partners. At Deutsche Banc Alex. Brown he served as Managing Director and Global Co-Head of Healthcare Investment Banking. At Thomas Weisel Partners he served on the Investment Committee for TWP’s Health Care venture fund as well as Co-Director of Healthcare Investment Banking. He holds an A.B. from Harvard College (Phi Beta Kappa), an M.B.A. from Harvard Business School and a J.D. from Harvard Law School. Mr. Scopa serves on the boards of directors of Astute Medical, Inc., iPierian, Solasia Pharma K.K., and TriVascular, Inc., and has previously served on the board of Peplin, Inc. (sold to LEO Pharmaceuticals).

Harold Van Wart

Dr. Harold E. Van Wart, Ph.D., is an Independent Director of Conatus Pharmaceuticals Inc., since March 2007. He has served as Metabolex, Inc.’s Chief Executive Officer since 2003, a member of its board of directors since January 2003, and President since April 2001. He served as Chief Operating Officer from December 2002 to January 2003 and Senior Vice President, Research and Development from October 2000 to December 2002. From 1999 to 2000, he was vice president and therapy head for arthritis and fibrotic diseases at Roche Biosciences, a division of Syntex (U.S.A.) Inc., a biopharmaceutical company. From 1992 to 1999, he was vice president and director of the institute of biochemistry and cell biology at Syntex (U.S.A.) Inc., a biopharmaceutical company acquired by an affiliate of Roche Holding Ltd in 1994. From 1978 to 1992, Dr. Van Wart served on the faculty of Florida State University. Dr. Van Wart holds a Ph.D. from Cornell University and a B.A. from SUNY Binghamton. He serves on the Emerging Companies and Health Section Governing Boards of BIO, as well as on its board of directors.